ArticleJournal of immunology research2026
CD39 Expression in Peripheral CD4+ T Lymphocytes Is Associated With Disease Activity in Patients With Systemic Lupus Erythematosus.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting FOXP3 and Regulatory T Cells in Systemic Lupus Erythematosus: Emerging Therapeutic Strategies and Clinical Prospects.Journal of cellular biochemistry · 2026Review
- CD39 Expression in Peripheral CD4+ T Lymphocytes Is Associated With Disease Activity in Patients With Systemic Lupus Erythematosus.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveRegulatory T cells (Tregs) and CD4-positive T cells are crucial for the immunological control of systemic lupus erythematosus (SLE). As a crucial component of the adenosine metabolism pathway, CD39 influences the development and functionality of several immune system lymphocyte subsets, such as CD4-positive T cells and Tregs. The purpose of this study was to examine the connection between the activity of SLE disease and the numbers of Tregs and CD4-positive T lymphocytes, as well as the expression levels of the CD39 molecule on these cells.
methodsOne hundred and eight SLE patients had peripheral blood drawn. The patients were split into two distinct categories: the SLE active group and the SLE low-activity group, depending on the illness activity. Using flow cytometry, the proportions and absolute numbers of CD4-positive T cells and Tregs, as well as the expression of CD39 on these cells, were measured. Their associations with SLE disease activity were examined. Last, CD39 was assessed as a possible biomarker for the activity of SLE illness.
resultsCompared to the SLE low-activity group, the SLE active group's peripheral blood had a larger percentage and quantity of CD4-positive T cells. In contrast, it was discovered that the SLE active group had fewer Tregs overall, both in terms of percentage and quantity, than the SLE low-activity group. Compared to those in the SLE low-activity group, patients in the SLE active group exhibited noticeably greater levels of CD39 expression in both Tregs and CD4-positive T cells. Additionally, this study showed a favorable correlation between the percentage and absolute quantity of Tregs and the expression level of CD39 on Tregs. On the other hand, there is a negative correlation between the percentage and absolute quantity of CD4-positive T cells and the expression level of CD39 on these cells. Furthermore, CD39 is a possible biomarker that could help in the identification of SLE disease activity, according to receiver operating characteristic (ROC) curve research.
conclusionAccording to this study, CD4-positive T cells' surface CD39 molecule serves a similar purpose to Tregs', namely immunological suppression. Therefore, a subpopulation of T cells with immunosuppressive properties is defined by CD4+CD39+ T lymphocytes, which may be a more accurate marker for differentiating disease activity in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.